Roche Signs a Clinical Program Agreement with Vaccibody to Evaluate VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer

 Roche Signs a Clinical Program Agreement with Vaccibody to Evaluate VB10.16 + Tecentriq (atezolizumab) for Advanced Cervical Cancer

Roche and AbbVie’s Venclexta (venetoclax) + Gazyva (obinutuzumab) Receive FDA’s Approval for Untreated Chronic Lymphocytic Leukemia

Shots:

  • Roche & Vaccibody collaborated to assess the combination of VB10.16 + Tecentriq in P-II, for 50 patients with advanced cervical cancer to evaluate its safety, tolerability, immunogenicity and efficacy
  • The combination trial agreement is built upon the trial assessing VB10.16 monothx in patients with precancerous cervical lesion. Vaccibody plans for the onset of P-II for the combination in H2’19
  • Tecentriq (atezolizumab) is a mAb inhibiting PD-L1 while blocking its interaction with PD-1 and B7.1 receptor. VB10.16 is a DNA vaccine, targeting HPV16 induced malignancies and is evaluated in P-I/IIa study for patients with pre-cancerous HPV16 induced high grade cervical intraepithelial neoplasia

Click here to read full press release/ article | Ref: Vaccibody | Image: Som

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post